🚨 Exciting news: Abstract Submission for #ADPD2026 is Now Open!. Submit your research, share your insights and help shape the future of neurodegenerative disease research and care. 🔍 Explore over 200+ abstract topics and start preparing your submission today. ➡️

📰 Big Data Insights: Blood Signatures of Cognitive Decline, Aging, APOE4 . “In the 'omics' era, where bigger is better, the Global Neurodegeneration Proteomics Consortium is making a splash. To date, this two-year-old initiative led by Gates Ventures and Johnson & Johnson has.

Only one week left until the abstract submission deadline! . Use the remaining days wisely, add the finishing touches to your abstract, and send us your work. Submitting an abstract to AD/PD™ 2026 will give you the chance to receive valuable feedback, present your findings to

🚨 Registration is NOW OPEN!. Be part of the breakthrough in #Parkinsons research 🧪.Join us for an exclusive event revealing how the iRS platform tracks alpha-synuclein misfolding to enable early detection of Parkinson’s — with over 90% accuracy. 📅 Date: 1 October 2025.👉.

Explore the impact of COVID-19 on brain neurodegenerative diseases at #ADPD2026!.Submit your research on topics such as the neuropathology of COVID-19, neuroimaging, neurological manifestations, comorbidities, CNS invasion of SARS-CoV-2, and the epidemiology in patients with

📰 New Type of Aβ42 Fibril Discovered in 83-Year-Old Man . “Thanks to cryo-electron microscopy, scientists have solved the structure of amyloid and tau fibrils—the hallmark protein pathologies of Alzheimer’s disease, and at the atomic level. As for Aβ42, they have described two.

The application for the AD/PD™ 2026 Junior Faculty Awards is open! 🏆 . If you are an early-career researcher looking to make a significant impact, this is your opportunity to be recognized. Submit your application by September 17, 2025, to be considered for this esteemed! 🔗

🎧 New AD/PD™ Session Spotlight out now!. In this episode, we highlight Plenary Lecture 05 from the AD/PD™ 2025 International Conference — “Pathogenic Mechanisms of Familial AD and Emerging Therapeutic Developments.”. Chaired by Prof. Manfred Windisch, the lecture was

If your research is on advancing patient care in #Alzheimers or #Parkinsons, don’t miss your chance to present at #ADPD2026! Share your insights on innovative, patient-centered care, support strategies, and impactful care models. The deadline is just 2 weeks away—bring your

📰A Tale of Two T Cells—Slowing Tau Spread, Shredding White Matter . “Meet the Jekyll and Hyde of the immune system: activated CD8⁺ T cells. On June 24 in Nature Immunology, researchers led by Dorian McGavern at the National Institutes of Health introduced a granzyme K-wielding.

Explore the latest research on Psychiatric Symptoms in Neurodegenerative Diseases at #ADPD2026! 📝. Submit abstracts on: .💠Disease Mechanisms & Pathophysiology .💠Therapeutic Targets & Treatment Mechanisms .💠Drug Development & Clinical Trials .💠Imaging, Biomarkers &

The field of Lysosomal Storage Diseases is evolving rapidly, and your research could be at the forefront of new breakthroughs. This is your opportunity to contribute to the global dialogue on neurodegenerative diseases and present your work at #ADPD2026! .🗓️ Submit your

📰T Cells from the Gut Occupy a Niche in Human and Mouse Brain | @alzforum. “The brain and spinal cord were once thought to enjoy immune privilege, meaning they were believed to be largely insulated from immune activity elsewhere in the body. In recent years, however, researchers

Copenhagen is the perfect backdrop for AD/PD™ 2026! . From its reputation as a cycling hub to its sustainability goals, rich culture, and world-class dining, this vibrant city offers the ideal setting for groundbreaking discussions in neurodegenerative disease research. Join us

With only one month remaining until the abstract submission deadline, now is the time to make some final touches to your abstract and submit your work! . We are eager to learn about the scope of your research in neurodegenerative mechanisms, diagnostic biomarkers, therapies,

We’re excited to let you know that registration for AD/PD™ 2026 is now open!. Secure your place for the world’s leading conference on Alzheimer’s and Parkinson’s diseases and related neurological disorders, taking place March 17–21, 2026, at the Bella Center Copenhagen, Denmark.

Breakthrough Alert in Parkinson’s Research! 🧪.This October, something big is coming and you won’t want to miss it. Get ready for an exclusive event that will unveil how alpha-synuclein misfolding, tracked using the powerful iRS platform, is revolutionizing the early detection.

Explore cutting-edge research in Demyelinating Diseases at #ADPD2026! . Submit abstracts on: .💠Therapeutic Targets & Mechanisms for Treatment .💠Imaging, Biomarkers & Diagnostics for better detection .💠Animal Models for understanding disease progression and testing therapies.

🎧 New AD/PD™ Session Spotlight out now!. In this episode, we unpack the key insights from Forum Discussion 04 — “Translational Drug Development in AD (Phase I–III) and Relevance for Treatment and Disease Modification: What Could Be Promising Strategies? Small Molecules for

📣Calling for abstracts for Theme G: Huntington’s and Other Neurodegenerative Diseases . This theme focuses on cutting-edge research on #Huntingtons disease and related neurodegenerative disorders, exploring novel insights and innovative therapeutic approaches. Submit your work

Don’t forget to stay informed with all the latest updates, important deadlines, program details, and speaker announcements leading up to next year’s conference!.📩Subscribe to our newsletter to get all the latest news & offers from AD/PD™ 2026🔗 .#ADPD